Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SOLID BIOSCIENCES INC.

(SLDB)
  Report
Delayed Nasdaq  -  04:00 2022-09-29 pm EDT
0.4682 USD   -2.46%
07:46aSolid Biosciences to Acquire Privately-Held Gene Therapy Firm AavantiBio
MT
07:14aLetter To The Duchenne Community : Strategic Update
PU
07:12aSolid Biosciences Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/23/2022 09/26/2022 09/27/2022 09/28/2022 09/29/2022 Date
0.5125(c) 0.5041(c) 0.49(c) 0.48(c) 0.4682(c) Last
196 748 268 470 194 477 717 156 533 475 Volume
-4.93% -1.64% -2.80% -2.04% -2.46% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 10,4 M - -
Net income 2022 -99,2 M - -
Net cash position 2022 104 M - -
P/E ratio 2022 -0,57x
Yield 2022 -
Sales 2023 5,68 M - -
Net income 2023 -105 M - -
Net cash position 2023 3,00 M - -
P/E ratio 2023 -0,62x
Yield 2023 -
Capitalization 52,9 M 52,9 M -
EV / Sales 2022 -4,92x
EV / Sales 2023 8,79x
Nbr of Employees 104
Free-Float 78,7%
More Financials
Company
Solid Biosciences Inc. is a life sciences company that is focused on developing transformative treatments to improve the lives of patients with Duchenne muscular dystrophy (Duchenne). Duchenne is a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are its gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a... 
More about the company
Ratings of Solid Biosciences Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about SOLID BIOSCIENCES INC.
07:46aSolid Biosciences to Acquire Privately-Held Gene Therapy Firm AavantiBio
MT
07:14aLetter To The Duchenne Community : Strategic Update
PU
07:12aSolid Biosciences Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of ..
AQ
07:01aSolid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Privat..
AQ
09/29Solid Biosciences to Participate at Upcoming Investor Conferences
AQ
09/19Solid Biosciences Inc.(NasdaqGS:SLDB) dropped from S&P G..
CI
08/18Bain Capital Engages in Discussions with Solid Biosciences
CI
08/12Chardan Research Adjusts Price Target on Solid Biosciences to $6 From $7, Reiterates Bu..
MT
08/11Solid Biosciences : Provides Second Quarter 2022 Business Update and Financial Results - F..
PU
08/11Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results
AQ
08/11SOLID BIOSCIENCES INC. Management's Discussion and Analysis of Financial Condition and..
AQ
08/11Solid Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months E..
CI
07/29Top Premarket Decliners
MT
06/23Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences
AQ
06/09Solid Biosciences Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
More news
News in other languages on SOLID BIOSCIENCES INC.
07:46aSolid Biosciences va acquérir la société privée de thérapie génique AavantiBio
08/18Bain Capital engage des discussions avec Solid Biosciences
08/11Solid Biosciences Inc. annonce ses résultats pour le deuxième trimestre et les six mois..
04/27Solid Biosciences annonce une mise à jour de ses priorités stratégiques pour se concent..
04/27Joel Schneider a l'intention de démissionner de son poste de directeur de l'exploitatio..
More news
Analyst Recommendations on SOLID BIOSCIENCES INC.
More recommendations
ETFs positioned on SOLID BIOSCIENCES INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Nasdaq US Biotechnology (D) - USD0.01%0.80%United_States
IShares Nasdaq US Biotechnology - USD0.01%0.84%United_States
IShares Biotechnology ETF - USD0.01%1.20%-NC
Invesco Nasdaq Biotechnology ETF - USD0.01%1.85%-United_States
More ETFs positioned on SOLID BIOSCIENCES INC.
Chart SOLID BIOSCIENCES INC.
Duration : Period :
Solid Biosciences Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOLID BIOSCIENCES INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 0,47 $
Average target price 5,50 $
Spread / Average Target 1 075%
EPS Revisions
Managers and Directors
Ilan Ganot President, Chief Executive Officer & Director
Stephen J. DiPalma Chief Financial Officer & Treasurer
Ian Frederick Smith Executive Chairman
Carl Morris Senior Vice President-Research & Development
Roxana Donisa Dreghici Senior VP, Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SOLID BIOSCIENCES INC.-73.25%53
GILEAD SCIENCES, INC.-13.14%79 050
VERTEX PHARMACEUTICALS33.33%75 091
REGENERON PHARMACEUTICALS, INC.9.55%73 961
BIONTECH SE-48.18%32 467
WUXI APPTEC CO., LTD.-38.82%29 383